Experimental combo aims to tackle stubborn colorectal cancer

NCT ID NCT07147231

First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times

Summary

This trial is testing whether combining pidnarulex (a drug that blocks cancer cell growth) with cemiplimab (an immunotherapy that helps the immune system attack cancer) is safe and effective for people with advanced colorectal cancer that no longer responds to standard treatments. The study has two phases: first, finding the best dose of pidnarulex, then comparing the combination against pidnarulex alone in 86 participants. It focuses on a specific type called microsatellite stable (MSS) colorectal cancer, which is harder to treat.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Pidnarulex (CX-5461) and cemiplimab (Libtayo)

What this could lead to

If successful, this could offer a new treatment option for people with advanced colorectal cancer that hasn't responded to other therapies.

What could go wrong

This is an early-phase trial (phase 1/2) with a small number of participants, so the combination may not prove effective or safe enough for wider use. Side effects from the drugs are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Emory Saint Joseph's Hospital

    RECRUITING

    Atlanta, Georgia, 30342, United States

    Contact

    Contact Phone: •••-•••-••••

  • Emory University Hospital Midtown

    RECRUITING

    Atlanta, Georgia, 30308, United States

    Contact

    Contact Phone: •••-•••-••••

  • Emory University Hospital/Winship Cancer Institute

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact

    Contact Phone: •••-•••-••••

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    RECRUITING

    Baltimore, Maryland, 21287, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Maryland/Greenebaum Cancer Center

    RECRUITING

    Baltimore, Maryland, 21201, United States

    Contact

    Contact Phone: •••-•••-••••